Page 28 - TD-1-1

Tumor Discovery Monocytes from single-cell analysis

139. Escobar G, Barbarossa L, Barbiera G, et al., 2018, Interferon therapy. N Engl J Med, 379(1): 64–73.
gene therapy reprograms the leukemia microenvironment https://doi.org/10.1056/NEJMra1706169
inducing protective immunity to multiple tumor antigens.
Nat Commun, 9: 2896. 143. Green DS, Nunes AT, David-Ocampo V, et al., 2018, A phase
1 trial of autologous monocytes stimulated ex vivo with
140. Gubin MM, Esaulova E, Ward JP, et al., 2018, High- sylatron (peginterferon alfa-2b) and actimmune (interferon
dimensional analysis delineates myeloid and lymphoid gamma-1b) for intra-peritoneal administration in recurrent
compartment remodeling during successful immune- ovarian cancer. J Transl Med, 16(1): 196.
checkpoint cancer therapy. Cell, 175(4): 1443.
https://doi.org/10.1186/s12967-018-1569-5
https://doi.org/10.1016/j.cell.2018.09.030 144. Liu Y, Cao X, 2015, The origin and function of tumor-
141. Yin M, Guo Y, Hu R, et al., 2020, Potent BRD4 inhibitor associated macrophages. Cell Mol Immunol, 12: 1–4.
suppresses cancer cell-macrophage interaction. Nat https://doi.org/10.1038/cmi.2014.83
Commun, 11(1): 1833.
145. Noy R, Pollard JW, 2014, Tumor-associated macrophages:
https://doi.org/10.1038/s41467-020-15290-0 From mechanisms to therapy. Immunity, 41(1): 49–61.
142. June CH, Sadelain M, 2018, Chimeric antigen receptor https://doi.org/10.1016/j.immuni.2014.06.010

Volume 1 Issue 1 (2022) 19 https://doi.org/10.36922/td.v1i1.4